Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Physical Gold ETF (AAAU) vs Novartis AG (NVS) Price & Performance

Goldman Sachs Physical Gold ETF
Novartis AG

Price performance

Price movement over the last 24 hours

Key statistics

Goldman Sachs Physical Gold ETF vs Novartis AG — how do they compare? Goldman Sachs Physical Gold ETF trades at $39.94, while Novartis AG trades at $155.54 (market cap $298.98B). The key difference: Novartis AG pays a 3.02% dividend while Goldman Sachs Physical Gold ETF pays none, and Novartis AG is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.

AAAUNVS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$53.21$168.62
52-Week Low
$32.29$113.50
Market Cap
$298.98B
Enterprise Value
$339.00B
Dividend Yield
3.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Physical Gold ETF

AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.

Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.

Novartis AG

Novartis (NVS) trades at $157.03, down 1.79% with mixed technical signals showing bullish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $56.67B revenue, 23.92% net margin, and robust cash flow generation. Recent developments include multiple strategic acquisitions and regulatory approvals expanding the oncology pipeline, though earnings have shown volatility with two misses in the last four quarters.

NVS presents a balanced investment case with strong profitability and pipeline expansion offset by valuation concerns and earnings inconsistency. The stock offers stability through defensive healthcare exposure but faces execution risks from integration challenges and competitive pressures in pharmaceutical markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goldman Sachs Physical Gold ETF

AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.

Read more on AAAU

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS